Campbell Tiley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Campbell Tiley has a total of 281 co-authors. Here are the top co-authors by number of shared publications:
- Judith Trotman
Concord Repatriation General Hospital University of Sydney Sydney New South Wales Australia
28 shared publications - Mark Hertzberg
Department of Haematology, Prince of Wales Hospital
28 shared publications - Fernando Roncolato
St George Hospital, Kogarah, Australia
26 shared publications - Henry Miles Prince
Sir Peter MacCallum Department of Oncology University of Melbourne Parkville Victoria Australia
26 shared publications - Claire Melissa Vajdic
Kirby Institute, University of New South Wales Sydney New South Wales Australia
25 shared publications - Craig R. Underhill
Albury-Wodonga Regional Cancer Centre, Albury-Wodonga, Australia
25 shared publications
Latest Publications
- Open Access
- 26 March 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-11
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012–2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for.
- 26 March 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-11
Open AccessHow comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
Despite an increasing desire to use historical cohorts as “synthetic” controls for new drug evaluation, limited data exist regarding the comparability of real-world outcomes to those in clinical trials. Governmental cancer data often lacks details on treatment, response, and molecular characterization of disease sub-groups. The Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (ALLG NBCR) includes source information on morphology, cytogenetics, flow cytometry, and molecular features linked to treatment received (including transplantation), response to treatment, relapse, and survival outcome. Using data from 942 AML patients enrolled between 2012–2018, we assessed age and disease-matched control and interventional populations from published randomized trials that led to the registration of midostaurin, gemtuzumab ozogamicin, CPX-351, oral azacitidine, and venetoclax. Our analyses highlight important differences in real-world outcomes compared to clinical trial populations, including variations in anthracycline type, cytarabine intensity and scheduling during consolidation, and the frequency of allogeneic hematopoietic cell transplantation in first remission. Although real-world outcomes were comparable to some published studies, notable differences were apparent in others. If historical datasets were used to assess the impact of novel therapies, this work underscores the need to assess diverse datasets to enable geographic differences in treatment outcomes to be accounted for.
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 3 shows the distribution of total hours per week at four decade years
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 3 shows the distribution of total hours per week at four decade years
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Data from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Background:Epidemiologic evidence suggests an inverse association between sun exposure and follicular lymphoma risk.Methods:We conducted an Australian population-based family case–control study based on 666 cases and 459 controls (288 related, 171 unrelated). Participants completed a lifetime residence and work calendar and recalled outdoor hours on weekdays, weekends, and holidays in the warmer and cooler months at ages 10, 20, 30, and 40 years, and clothing types worn in the warmer months. We used a group-based trajectory modeling approach to identify outdoor hour trajectories over time and examined associations with follicular lymphoma risk using logistic regression.Results:We observed an inverse association between follicular lymphoma risk and several measures of high lifetime sun exposure, particularly intermittent exposure (weekends, holidays). Associations included reduced risk with increasing time outdoors on holidays in the warmer months [highest category OR = 0.56; 95% confidence interval (CI), 0.42–0.76; Ptrend < 0.01], high outdoor hours on weekends in the warmer months (highest category OR = 0.71; 95% CI, 0.52–0.96), and increasing time outdoors in the warmer and cooler months combined (highest category OR = 0.66; 95% CI, 0.50–0.91; Ptrend 0.01). Risk was reduced for high outdoor hour maintainers in the warmer months across the decade years (OR = 0.71; 95% CI, 0.53–0.96).Conclusions:High total and intermittent sun exposure, particularly in the warmer months, may be protective against the development of follicular lymphoma.Impact:Although sun exposure is not recommended as a cancer control policy, confirming this association may provide insights regarding the future control of this intractable malignancy.
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Background:Epidemiologic evidence suggests an inverse association between sun exposure and follicular lymphoma risk.Methods:We conducted an Australian population-based family case–control study based on 666 cases and 459 controls (288 related, 171 unrelated). Participants completed a lifetime residence and work calendar and recalled outdoor hours on weekdays, weekends, and holidays in the warmer and cooler months at ages 10, 20, 30, and 40 years, and clothing types worn in the warmer months. We used a group-based trajectory modeling approach to identify outdoor hour trajectories over time and examined associations with follicular lymphoma risk using logistic regression.Results:We observed an inverse association between follicular lymphoma risk and several measures of high lifetime sun exposure, particularly intermittent exposure (weekends, holidays). Associations included reduced risk with increasing time outdoors on holidays in the warmer months [highest category OR = 0.56; 95% confidence interval (CI), 0.42–0.76; Ptrend < 0.01], high outdoor hours on weekends in the warmer months (highest category OR = 0.71; 95% CI, 0.52–0.96), and increasing time outdoors in the warmer and cooler months combined (highest category OR = 0.66; 95% CI, 0.50–0.91; Ptrend 0.01). Risk was reduced for high outdoor hour maintainers in the warmer months across the decade years (OR = 0.71; 95% CI, 0.53–0.96).Conclusions:High total and intermittent sun exposure, particularly in the warmer months, may be protective against the development of follicular lymphoma.Impact:Although sun exposure is not recommended as a cancer control policy, confirming this association may provide insights regarding the future control of this intractable malignancy.
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 2 shows the factors considered in the directed acyclic graph for sun exposure and follicular lymphoma risk
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 2 shows the factors considered in the directed acyclic graph for sun exposure and follicular lymphoma risk
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 1 shows the exclusions for cases and controls during the recruitment processes
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 1 shows the exclusions for cases and controls during the recruitment processes
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 3 shows the distribution of total hours per week at four decade years
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 3 shows the distribution of total hours per week at four decade years
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 4 shows the estimated trajectories of outdoor hours by control type for warmer months (A and B), cooler months (C and D) and total (E and F)
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 4 shows the estimated trajectories of outdoor hours by control type for warmer months (A and B), cooler months (C and D) and total (E and F)
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 4 shows the estimated trajectories of outdoor hours by control type for warmer months (A and B), cooler months (C and D) and total (E and F)
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 4 shows the estimated trajectories of outdoor hours by control type for warmer months (A and B), cooler months (C and D) and total (E and F)
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 2 shows the factors considered in the directed acyclic graph for sun exposure and follicular lymphoma risk
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Figure 2 shows the factors considered in the directed acyclic graph for sun exposure and follicular lymphoma risk
- Open Access
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1a-3d from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Tables 1a-3d. Supplementary Table 1a: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours. Supplementary Table 1b: Average posterior probability value and odds of correct classification for outdoor hours trajectory groups. Supplementary Table 1c: Estimated probability and the proportion of study members classified in each group according to the maximum posterior probability assignment rule. Supplementary Table 2a: Odds ratios and 95% confidence intervals for FL risk in relation to total lifetime outdoor hours during decade years among cases and related controls.Supplementary Table 2b: Odds ratios and 95% confidence intervals for FL risk in relation to outdoor hours on weekdays, weekends, and holidays at each decade year among cases and related controls. Supplementary Table 2c: Odds ratios and 95% confidence intervals for FL risk in relation to trajectories of outdoor hours across the decade years among cases and related controls. Supplementary Table 2d: Odds ratios and 95% confidence intervals for FL risk in relation to total lifetime outdoor hours during decade years among cases and unrelated controls. Supplementary Table 2e: Odds ratios and 95% confidence intervals for FL risk in relation to outdoor hours on weekdays, weekends, and holidays at each decade year among cases and unrelated controls. Supplementary Table 2f: Odds ratios and 95% confidence intervals for FL risk in relation to trajectories of outdoor hours across the decade years among cases and unrelated controls. Supplementary Table 3a: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours – cases and related controls. Supplementary Table 3b: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours – cases and unrelated controls. Supplementary Table 3c: Average posterior probability value and odds of correct classification for outdoor hours trajectory groups. Supplementary Table 3d: Estimated probability and the proportion of study members classified in each group according to the maximum posterior probability assignment rule.
- 9 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1a-3d from A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk
Supplementary Tables 1a-3d. Supplementary Table 1a: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours. Supplementary Table 1b: Average posterior probability value and odds of correct classification for outdoor hours trajectory groups. Supplementary Table 1c: Estimated probability and the proportion of study members classified in each group according to the maximum posterior probability assignment rule. Supplementary Table 2a: Odds ratios and 95% confidence intervals for FL risk in relation to total lifetime outdoor hours during decade years among cases and related controls.Supplementary Table 2b: Odds ratios and 95% confidence intervals for FL risk in relation to outdoor hours on weekdays, weekends, and holidays at each decade year among cases and related controls. Supplementary Table 2c: Odds ratios and 95% confidence intervals for FL risk in relation to trajectories of outdoor hours across the decade years among cases and related controls. Supplementary Table 2d: Odds ratios and 95% confidence intervals for FL risk in relation to total lifetime outdoor hours during decade years among cases and unrelated controls. Supplementary Table 2e: Odds ratios and 95% confidence intervals for FL risk in relation to outdoor hours on weekdays, weekends, and holidays at each decade year among cases and unrelated controls. Supplementary Table 2f: Odds ratios and 95% confidence intervals for FL risk in relation to trajectories of outdoor hours across the decade years among cases and unrelated controls. Supplementary Table 3a: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours – cases and related controls. Supplementary Table 3b: Bayesian information criterion for outdoor hours group-based trajectory model according to number of groups and trajectory outdoor hours – cases and unrelated controls. Supplementary Table 3c: Average posterior probability value and odds of correct classification for outdoor hours trajectory groups. Supplementary Table 3d: Estimated probability and the proportion of study members classified in each group according to the maximum posterior probability assignment rule.